enkephalin

enkephalin. Enkephalins are endogenous opioid peptides that function as critical neurotransmitters and neuromodulators within the central nervous system and peripheral nervous system. They are derived from the precursor protein proenkephalin and primarily act by binding to δ-opioid receptor and μ-opioid receptor sites. Their discovery in 1975 by researchers John Hughes and Hans Kosterlitz in Scotland provided the first direct evidence for an endogenous opioid system, fundamentally altering understanding of pain modulation, stress response, and reward pathways.

Structure and types

The primary enkephalins are pentapeptides, with the two major forms being methionine-enkephalin (Tyr-Gly-Gly-Phe-Met) and leucine-enkephalin (Tyr-Gly-Gly-Phe-Leu). These peptides share the common N-terminal sequence Tyr-Gly-Gly-Phe, which is a hallmark of the larger endogenous opioid family that includes β-endorphin and dynorphin. Structural studies, including those utilizing X-ray crystallography and nuclear magnetic resonance spectroscopy, reveal that their bioactive conformation is crucial for receptor interaction. Variations and longer peptides derived from proenkephalin, such as peptide E and BAM22P, also exhibit opioid activity and are found in tissues like the adrenal medulla.

Biosynthesis and metabolism

Enkephalins are synthesized as part of the large precursor molecule proenkephalin, encoded by the PENK gene located on human chromosome 8. Post-translational processing by specific enzymes, including prohormone convertase 1 and prohormone convertase 2, cleaves this precursor into the active peptides within secretory vesicles. Release occurs via calcium-dependent exocytosis in response to neuronal depolarization. Degradation is rapid, primarily mediated by membrane-bound peptidases such as neprilysin (also known as neutral endopeptidase) and aminopeptidase N, which are key targets for developing enzyme inhibitors to prolong enkephalin activity.

Physiological functions

Enkephalins modulate a wide array of physiological processes, most notably the inhibition of nociception within pain pathways of the spinal cord and brainstem. They are involved in the body's response to stress, influencing the hypothalamic-pituitary-adrenal axis and reducing anxiety-related behaviors. Within the mesolimbic pathway, enkephalins contribute to the regulation of reward and motivation, interacting with systems involving dopamine. Additional roles include the modulation of gastrointestinal motility, respiratory rate, and neuroendocrine functions.

Receptors and mechanism of action

Enkephalins exert their effects primarily by acting as agonists at G protein-coupled receptors, with highest affinity for the δ-opioid receptor (DOR) and significant activity at the μ-opioid receptor (MOR). Binding to these receptors activates inhibitory Gᵢ/o proteins, leading to the inhibition of adenylyl cyclase, reduced cyclic AMP production, and the opening of potassium channels via G protein-coupled inwardly-rectifying potassium channels. This results in neuronal hyperpolarization and a decrease in the release of excitatory neurotransmitters like glutamate and substance P, effectively dampening pain signal transmission.

Clinical significance

The enkephalin system is a major target for therapeutic intervention, particularly in the field of analgesia. Strategies include developing peptidase inhibitors like racecadotril to protect endogenous enkephalins from degradation, a concept known as enkephalinase inhibition. Dysregulation of the enkephalin pathway is implicated in conditions such as chronic pain disorders, major depressive disorder, and drug addiction. Research into selective δ-opioid receptor agonists seeks to provide pain relief with fewer side effects, such as respiratory depression and physical dependence, commonly associated with traditional morphine-like drugs that target the μ-opioid receptor.

History and discovery

The existence of an endogenous morphine-like substance was hypothesized following the identification of opioid receptors by Candace Pert and Solomon Snyder. In 1975, the isolation of enkephalins was achieved by John Hughes and Hans Kosterlitz at the University of Aberdeen from pig brain extracts. Their seminal paper, published in the journal Nature, demonstrated the peptides' ability to inhibit electrically-induced contractions of the mouse vas deferens and guinea pig ileum bioassays. This discovery catalyzed an entire field of neuropharmacology, leading to the characterization of the broader endogenous opioid system and earning the researchers numerous accolades, including the Lasker Award.